Method for producing a stabilized pharmaceutical composition in the form of an aqueous solution

LAP654AUndetermined Publication Date: 2025-02-21OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU NAUCHNO TEHNOLOGICHESKAYA FARMACEVTICHESKAYA FIRMA POLYSAN
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
LAP654
Authority / Receiving Office
LA · LA
Patent Type
Applications
Current Assignee / Owner
Priority Date
2016-09-29
Filing Date
2017-09-07
Publication Date
2025-02-21

AI Technical Summary

Technical Problem

Current methods for sterilizing pharmaceutical compositions containing thermolabile and hydrolytically unstable components, such as succinic acid, inosine, nicotinamide, and riboflavin mononucleotide, face challenges with standard thermal sterilization leading to degradation and microbial contamination, necessitating the development of a more effective stabilization and sterilization method.

Method used

The method involves dissolving succinic acid, inosine, nicotinamide, and riboflavin sodium mononucleotide in water, followed by sterilizing filtration, and adding pharmaceutically acceptable stabilizing agents like sodium hydroxide or sodium bicarbonate to achieve a stable pH range of 6.0 to 8.0, allowing for thermal sterilization at 100°C for 8 minutes to enhance stability and safety.

Benefits of technology

This approach results in a stable aqueous solution that maintains the biological activity of the components, is physiologically acceptable, and can withstand thermal exposure, thereby increasing the safety and shelf life of the pharmaceutical composition for intravenous administration.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to chemical and pharmaceutical industry and, in particular, to amethod for producing a stabilized pharmaceutical composition presented as an aqueous solutionthat may be used to obtain an intravenous drug containing succinic acid, nicotinamide, inosine andriboflavin mononucleotide as the active ingredients and possessing cytoprotective properties.The invention objective is to develop a method for producing the known stabilizedpharmaceutical composition presented as an aqueous solution that would enable to enhance itssafety in use through the application ofthermal sterilization. The objective is achieved by a method for producing a stabilized pharmaceuticalcomposition presented as an aqueous solution containing succinic acid, inosine, nicotinamide,riboflavin mononucleotide sodium as the active ingredients, by way ofdissolving them in waterwith subsequent sterile filtratioru wherein, in accordance with the invention, the composition issupplemented by one or several ofthe pharmaceutically acceptable components as the stabilizing agent to be selected from the goup including sodium hydroxide,tris(hydroxymethyl)aminomethane (TRIS), ethanolamine, diethanolamine, sodium carbonate,meglumine, up to a stable solution with pH from 6.0 to 8.0, the components' ratio,Tow! being asfollows: succinic acid 5.00-12.50 inosine 1.00-2.40 nicotinamide 0.50- 1.20 riboflavin mononucleotide sodium 0.10-0.24 stabilizing agent 3.21-51.30 water up to 100.00lo, and the solution is subjected to additional thermal sterilization at l00oC with exposure time of8minutes to I I 6'C with exposure time of 2 minutes.In a particular embodiment, the objective is achieved by adding sodium hydrocarbonate to the composition as the stabilizing agent, up to a stable solution with pH of 6.0 to 7.0, thecomponents' ratio,Yowl. being as follows: succinic acid 5'00-12.50 inosine 1.00-2.40 nicotinamide 0.50-1.20 riboflavin mononucleotide sodium 0.10-0.24
Need to check novelty before this filing date? Find Prior Art

Description

DESCRIPTION A METHOD FOR PRODUCING A STABILIZED PHARMACEUTICAL COMPOSITION IN THE FORM OF AN AQUEOUS SOLUTION Field of technology The invention relates to the chemical-pharmaceutical industry, in particular to a method for producing a stabilized pharmaceutical composition in the form of an aqueous solution, which can be used to produce a medicinal product for intravenous administration, containing succinic acid, nicotinamide, inosine and riboflavin mononucleotide as active components and having cytoprotective properties. Prior art The development of effective combination drugs for intravenous administration is an important technological challenge, since the use of highly reactive ingredients in such compositions very often leads to chemical interaction of the active components, with the formation of undesirable, often toxic impurities and degradation products at all stages of drug production. When producing sterile solutions of medicinal products, one of the most complex processes leading to the formation of unwanted impurities and reducing the safety of the drug is the process of terminal sterilization, which involves the complete destruction of all types of microorganisms and their spores. Currently, the most widely used terminal sterilization method in industrial pharmaceutical production is thermal sterilization with saturated steam under pressure (autoclaving). The parameters of this process are regulated in international pharmacopoeias (SP XIII, EP 9.0, USP 39). Standard sterilization of aqueous drug solutions with saturated steam is carried out at a temperature of 120-122°C under pressure for 8-15 minutes, depending on the physicochemical properties and other parameters of the object being thermally sterilized. However, in practice, we often encounter medicinal products that contain heat-labile medicinal substances, which do not allow the use of standard sterilization modes, and industrial technologies are currently used in combination with other methods of exposure (gamma radiation, ultrasound, etc.), including the use of chemical sterilization methods. Thus, application RU 2001117337 proposes a variant of radiation sterilization of solutions, while patent RU 2519841 proposes sterilization using microwave ultra-high-frequency radiation. In application B 2006142783, sterilization is carried out by treatment with pulsed high-voltage discharges generating sterilizing UV radiation, and application RU 2000130091 proposes a method for electrochemical sterilization of liquids using chemically active particles. Currently, combinations of thermal and physical sterilization modes are also used to sterilize unstable aqueous solutions: for example, in patent RU 2238108, heating is carried out by exposure to a microwave electromagnetic field, and sterilization is carried out by an ultra-high frequency electromagnetic field. Application RU 2003115619 proposes an original combined method of sterilization using an electric field and acoustic vibration. However, since many combined non-standard sterilization methods do not provide a high guarantee of the absence of microbial contamination of the drug, various water-soluble antimicrobial preservatives permitted by international pharmacopoeias are often added to the solution during its preparation: benzyl alcohol (RU 2209070, RU 210550, RU 2326669, RU 2192855, US 20150126466, UA 26343), benzalkonium chloride (RU 2419417, UA 26343), chlorobutanol (UA 26343), metacresol (RF 2093144), cresol (RU 2020954), phenol (RU 2111012). This combined method allows sterilization of heat-labile drugs under non-standard sterilization conditions, but it has a very significant drawback - a limitation on medical use, especially in pediatric practice; (SP XIII, OFS .1.1.0016.15 Sterilization). It should be noted that parenteral medications based on succinic acid are widely known in medical practice. In most of the described examples, the standard pharmacopoeial sterilization regime of 120-122°C for 8-15 minutes is used for sterilizing multicomponent preparations based on aqueous solutions of succinic acid (patents EA 000879, EA 007865, RU 2536994, and RU 2549448). It is known that for compositions containing heat-labile components, the use of standard sterilization modes leads to degradation of the ingredients with the formation of an unacceptable level of decomposition products. Thus, determining the optimal temperature regime for sterilization of multicomponent compositions based on succinic acid, additionally containing heat-labile ingredients, is a crucial task in the development of new drugs. A method for producing a combination drug containing a composition of succinic acid, inosine, nicotinamide, and riboflavin mononucleotide is known. It is described in patent EA 001099 and has been selected as a prototype. The method involves dissolving the above ingredients in water, filtering through a sterilizing filter, filling into sterile ampoules at room temperature, and sealing without further heat sterilization of the final product. This method for obtaining a composition containing hydrolytically unstable inosine and nicotinamide, as well as heat-labile riboflavin mononucleotide, 1has a significant drawback inherent in sterilization by filtration under aseptic conditions, namely, a potentially high probability of contamination by microorganisms during preparation of the drug, since sterilizing filtration using a standard filter with a pore size of 0.22 μm creates a reliable barrier for bacteria, but often does not retain spores, viruses and mycoplasmas, which reduces the safety of the solution during use. In addition, it is obvious that the failure of the prototype to undergo the standard thermal sterilization stage for 8-15 minutes at 120-122°C is due to the thermal and hydrolytic instability of the ingredients included in the composition. Disclosure of invention The objective of the invention is to develop a method for producing a stabilized pharmaceutical composition of a known composition in the form of an aqueous solution, which makes it possible to increase its safety during use through the use of thermal sterilization. The stated problem is solved in that in the method for obtaining a stabilized pharmaceutical composition in the form of an aqueous solution containing succinic acid, inosine, nicotinamide, sodium riboflavin mononucleotide as active components by dissolving them in water followed by sterilizing filtration, according to the invention, one or more pharmaceutically acceptable components selected from the group including sodium hydroxide, trisoxymethylaminomethane (TRIS), ethanolamine, disethanolamine, sodium carbonate, meglumine are additionally introduced into the composition as a stabilizing agent until a stable solution is obtained with a pH value in the range from 6.0 to 8.0 with the following ratio of components, mass. %: succinic acid 5.00- 12, 50 inosine 1.00-2.40 nicotinamide 0.50-1.20 sodium riboflavin mononucleotide 0.10-0.24 stabilizing agent 3.21-51.30 ι water up to 100.0%, and additionally carry out thermal sterilization of the solution at a temperature from 100°C and an exposure time of 8 minutes to 116°C and an exposure time of 2 minutes. In a particular case, the stated problem is solved by introducing sodium bicarbonate into the composition as a stabilizing agent until a stable solution with a pH value in the range of 6.0-7.0 is obtained, with the following ratio of components, mass%: succinic acid 5.00- 12, 50 inosine 1.00-2.40 nicotinamide 0.50-1.20 riboflavin mononucleotide sodium 0.10-0.24 sodium bicarbonate 13.70-17.20 water up to 100.0%. In addition, in a particular case, the problem is solved by the fact that sodium bicarbonate is additionally introduced into the composition as a stabilizing agent until a stable solution is obtained with a pH value in the range of 6.4-7.4, with the following ratio of components, wt.%: succinic acid 5.00- 12, 50 inosine 1.00-2.40 nicotinamide 0.50-1.20 sodium riboflavin mononucleotide 0.10-0.24 stabilizing agent 3.21- 33, About sodium bicarbonate 0.10-2.90 water up to 100.0%. In the claimed method for producing a stabilized pharmaceutical composition, one or more pharmaceutically acceptable components selected from are additionally introduced into it as a stabilizing agent. group including sodium hydroxide, trisoxymethylaminomethane (TRIS), ethanolamine, diethanolamine, sodium carbonate, meglumine. This group consists of substances that are pharmaceutically acceptable for a composition containing succinic acid, inosine, nicotinamide, sodium riboflavin mononucleotide as active components, and allows preserving the spectrum of biological activity of the composition. In this case, the quantitative content of the stabilizing agent, which is either the individual components listed above or their various combinations, is selected empirically to obtain stable aqueous solutions with a pH value in the range from 6.0 to 8.0. In addition, as a result of the experiments, it was revealed that the addition of sodium bicarbonate to the known composition as a stabilizing agent or in addition to it makes it possible to obtain a stable aqueous solution with a narrower pH range from 6.0 to 7.0 and from 6.4 to 7.4, which are also physiologically acceptable pH values ​​for intravenous administration of the drug. The present inventors have established for the first time the effect of one or more pharmaceutically acceptable components selected from the group consisting of sodium hydroxide, trisoxymethylaminomethane (TRIS), ethanolamine, diethanolamine, sodium carbonate, meglumine, and sodium bicarbonate on the stability of an aqueous solution containing hydrolytically unstable components such as nicotinamide and inosine, as well as the thermolabile riboflavin mononucleotide, upon thermal exposure. The resulting solution has a physiologically acceptable pH range and is stable during long-term storage. Thus, the stabilizing agent does not allow the destruction of the specified active components under the influence of temperature, which made it possible to additionally carry out thermal sterilization of the solution and thereby increase its safety when used as a solution for intravenous administration in medical practice. Embodiments of the invention | The implementation of the claimed method for obtaining a stabilized pharmaceutical composition in the form of an aqueous solution can be illustrated by the examples below. At the initial stage, to study the factors influencing the stability of the new composition, an aqueous solution containing active components similar to the prototype was studied, by weight: succinic acid 10.0 wt.%, inosine 2.0 wt.%, nicotinamide 1.0 wt.% and riboflavin mononucleotide 0.2 wt.%, water for injection up to 100.0 wt.% obtained in Example 1. Example 1. 50.0 l of water for injection, 10.0 kg of succinic acid, 2.0 kg of inosine, 1.0 kg of nicotinamide, and 0.2 kg of riboflavin mononucleotide are loaded into a 100 l apparatus with a stirrer. The mixture is stirred until the components are completely dissolved while heating to 40-60°C, and the volume of the solution is then brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules, and sealed. Studies have shown that the composition obtained in Example 1 is unstable after cooling the solution In the ampoules, a precipitate of the original least water-soluble ingredient, inosine, formed at room temperature. To obtain the threshold values ​​of solubility of the prototype ingredients, three model compositions were obtained with different contents of active components while maintaining the molar ratios of the active substances (examples 2, 3, 4). Example 2. 50.0 l of water for injection, 7.5 kg of succinic acid, 1.5 kg of inosine, 0.75 kg of nicotinamide, 0.15 kg of riboflavin mononucleotide are loaded into a 100 l apparatus with a stirrer, and the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Each 10 ml ampoule contains succinic acid 750 mg (7.5 wt.%), inosine 150 mg (1.5 wt.%), nicotinamide 75 mg (0.75 wt.%), sodium riboflavin-5 mononucleotide 15 mg (0.15 wt.%), water for injection to 100.0 wt.%. Example 3. 50.0 l of water for injection, 5.0 kg of succinic acid, 1.0 kg of inosine, 0.5 kg of nicotinamide, 0.1 kg of riboflavin mononucleotide are loaded into a 100 l apparatus with a stirrer, and the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Each 10 ml ampoule contains: succinic acid 500 mg (5.0 wt.%), inosine 100 mg (1.0 wt.%), nicotinamide 50 mg (0.5 wt.%), sodium riboflavin mononucleotide 10 mg (0.1 wt.%), water for injection to 100.0 wt.%. Example 4. 50.0 l of water for injection, 2.5 kg of succinic acid, 0.5 kg of inosine, 0.25 kg of nicotinamide, 0.05 kg of riboflavin mononucleotide, bring the volume of the solution to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Each 10 ml ampoule contains - succinic acid 250 mg (2.5 wt.%), inosine 50 mg (0.5 wt.%), nicotinamide 25 mg (0.25 wt.%), riboflavin-5-mononucleotide sodium 5 mg (0.05 wt.%), water for injection to 100.0 wt.%. Observation of the drug samples showed that in the solution obtained in Example 2, an inosine precipitate also gradually formed, while the compositions obtained in Examples 3 and 4 did not form an inosine precipitate and were suitable for further study. The results of the study of the solution obtained in Example 3, containing the maximum concentrations of active components, which was additionally subjected to thermal sterilization at various temperatures in the range of 100-120 C° with a standard holding time of 8 minutes are given in Example 5. Example 5. A 100-liter apparatus with a stirrer is loaded with 50.0 liters of water for injection, 5.0 kg of succinic acid, 1.0 kg of inosine, 0.5 kg of nicotinamide, and 0.1 kg of riboflavin mononucleotide. The volume of the solution is brought to 100 liters with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10-ml ampoules, and sealed. The ampoules are then thermally sterilized with water vapor under pressure in the temperature range from 100±1 to 121±1 °C for 8 minutes. Each 10 ml ampoule contains: succinic acid 500 mg (5.0 wt.%), inosine 100 mg (1.0 wt.%), nicotinamide 50 mg (0.5 wt.%), riboflavin mononucleotide 10 mg (0.1 wt.%), water for injection up to 100.0 wt.%. Before and after sterilization, the quantitative content of active components and the level of impurities formed during sterilization were determined using the HPLC method (Table 1). The quantitative content of active ingredients and impurities was determined by the HPLC method under the following conditions: spectrophotometric detector, wavelength 254 nm, refractometric detector, chromatographic column Phenomenex Luna Phenyl -Hexyl, 250 mm long, with an internal diameter of 4.6 mm, packed with a sorbent with a grain size of 5 μm, or similar; eluent flow rate 0.7 ml / min, column temperature 25DC; chromatography time 30 min. Table 1 Thermal sterilization of the composition The composition obtained according to example 5 does not withstand the standard thermal sterilization regime (121±1°C, 8 min) - the active components decompose with the formation of degradation products - nicotinic acid, hypoxanthine and unidentified impurities. The 100±1°C for 8 minutes mode also does not ensure an acceptable level of impurities in the solution. Thus, the initial stage of research indicates that the composition obtained in Example 5 is an aqueous solution of chemically active, heat-labile, and hydrolyzable components, which are prone to degradation during thermal sterilization and storage, forming numerous unidentifiable impurities that pose a potential hazard for medical use. Furthermore, the resulting solution had a non-physiological pH of 3.15, which also precludes its use as an intravenous drug. An attempt to reduce the risk of contamination by microorganisms under conditions of aseptic filling of the medicinal composition and by introducing auxiliary components that are chemical preservatives, such as benzyl alcohol, benzalkonium chloride, cresol, propylene glycol in a concentration of 0.5-5.0%, also turned out to be unsuccessful, since when they were added, crystallization from the solution of the mixture of active components and a change in the color of the solution occurred, which indicated a chemical interaction of the active components with auxiliary components. An attempt to sterilize the prototype composition using alternative methods of physicochemical sterilization (radiation, microwave) also proved unsuccessful due to the rapid degradation of sodium riboflavin mononucleotide with the formation of colored decomposition products and sediment. At the next stage, studies were carried out on a model composition with an optimal physiological pH value of 7.3-7.4 corresponding to the pH of human blood, suitable for further thermal sterilization, while sodium hydroxide was introduced into the composition as a stabilizing component (examples 6-11). Example 6. 50.0 l of water for injection, 5 kg of succinic acid, 1.0 kg of inosine, 0.5 kg of nicotinamide, 0.1 kg of riboflavin mononucleotide and 3.40 kg of sodium hydroxide are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and the pH of the solution is established at 7.3-7.4, and then the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Example 7. 50.0 l of water for injection, 7.5 kg of succinic acid, 1.5 kg of inosine, 0.75 kg of nicotinamide, 0.15 kg of riboflavin mononucleotide and 8.51 kg of sodium hydroxide are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and the pH is set to 7.3-7.4, and then the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Example 8. 50.0 l of water for injection, 10 kg of succinic acid, 2.0 kg of inosine, 1.0 kg of nicotinamide, 0.2 kg of riboflavin mononucleotide and 6.81 kg of sodium hydroxide are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and the pH is established at 7.3-7.4, and then the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Example 9. 50.0 l of water for injection, 12.5 kg of succinic acid, 2.5 kg of inosine, 1.25 kg of nicotinamide, 0.25 kg of riboflavin mononucleotide and sodium hydroxide8, 52 kg of water for injection are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and the pH is set to 7.3-7.4, and then the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Example 10. 50.0 l of water for injection, 15 kg of succinic acid, 3.0 kg of inosine, 1.5 kg of nicotinamide, 0.3 kg of riboflavin mononucleotide and sodium hydroxide, 22 kg of sodium hydroxide are loaded into a 100 l apparatus with a stirrer until a pH of 7.3-7.4 is established, and then the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Example 11. 50.0 l of water for injection, 20 kg of succinic acid, 4.0 kg of inosine, 2.0 kg of nicotinamide, 0.4 kg of riboflavin mononucleotide and 62 kg of sodium hydroxide13 are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and a pH of 7.3-7.4 is established, and then the volume of the solution is brought to 100 l with water for injection. In the resulting composition, complete dissolution of the components could not be achieved - the solution was a yellow homogeneous suspension. The effectiveness of using sodium hydroxide as a solubilizer for the resulting solutions was assessed over a period of 10 days after filling into ampoules (Table 2) by visually analyzing 100 ampoules for changes in the state of aggregation (precipitation) and color changes. solution. The resulting samples were stored in a Binder KBF 240 climate chamber at 25°C. Table 2 Results of observation of compositions containing sodium hydroxide as a solubilizer according to examples 6-11. The experiments showed that the addition of sodium hydroxide to a composition similar to the prototype (succinic acid 10.0 wt.%, inosine 1.0 wt.%, nicotinamide 0.5 wt.% and riboflavin mononucleotide 0.2 wt.%, water up to 100.0 wt.%) allowed the active components to be completely dissolved (Example 8). Aqueous solutions of the composition with a concentration of active components 1.25 and 1.5 times higher (Signs 9 and 10) and two times lower (Example 6) were also successfully solubilized. The composition with the content of active components twice as large as in the prototype (Example 11) it was not possible to solubilize with sodium hydroxide to a true solution. Since the influence of the acidity of the medium and the sterilization temperature of multicomponent aqueous solutions is largely determined by a combination of empirical factors, for further research we determined the limits of the content of active components corresponding to the prototype: succinic acid 5.0-12.5, inosine 1.0-2.5, nicotinamide 0.5-1.25, riboflavin mononucleotide 0.1-0.25 wt.%, which, after the addition of the stabilizing agent sodium hydroxide, give a stable true solution for 10 days after filling into ampoules before the thermal sterilization process. Next, to determine the pH ranges that ensure the stability of solutions potentially suitable for subsequent heat sterilization, model solutions of W1, W2, and N'3 were prepared with varying amounts of sodium hydroxide to simulate pharmaceutically acceptable solution pH values ​​in the range of 5.4–8.4 (Examples 12, 13, 14). The resulting solutions in ampoules were placed in a Bindern climate chamber at a temperature of 60±2°C for 3 days to conduct stress tests, after which the state of the solutions was visually assessed. The results are presented in Table 3. Example 12. (Model solution NK). 50.0 L of water for injection, 5.0 kg of succinic acid, 0.5 kg of nicotinamide, 1.0 kg of inosine, 0.1 kg of riboflavin mononucleotide, and sodium hydroxide are loaded into a 100 L apparatus with a stirrer to ensure a pH in the range of 5 1 , 4 to 8.4, bring the volume of the solution to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with 0.22 µm pore diameter, poured into 10 ml ampoules and sealed. Each 10 ml ampoule contains: succinic acid 500 mg (5.0 wt.%), inosine 100 mg (1.0 wt.%), nicotinamide 50 mg (0.5 wt.%), riboflavin mononucleotide 10 mg (0.1 wt.%), sodium hydroxide from 2.80 to 3.49 wt.%, water for injection up to 100.0 wt.%. Example 13. (Model solution No. 2). 50.0 l of water for injection, 10.0 kg of succinic acid, 0.5 kg of nicotinamide, 1.0 kg of inosine, 0.1 kg of riboflavin mononucleotide and sodium hydroxide to ensure a pH in the range from 5.4 to 8.4 are loaded into a 100 l apparatus with a stirrer; the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide from 5.60 to 6.98 wt.%, water for injection up to 100.0 wt.%. Example 14. (Model solution Y'3). 50.0 L of water for injection, 12.5 kg of succinic acid, 1.25 kg of nicotinamide, 2.5 kg of inosine, 0.25 kg of riboflavin mononucleotide and sodium hydroxide to ensure a pH in the range from 5.4 to 8.4 are loaded into a 100 L apparatus with a stirrer; the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Each 10 ml ampoule contains: succinic acid 1250 mg (12.5 wt.%), inosine 250 mg (1.25 wt.%), nicotinamide 125 mg (1.25 wt.%), riboflavin Mononucleotide 25 mg (0.25 wt.%), sodium hydroxide from 7.01 to 8.72 wt.%, water for injection up to 100.0 wt.%. The conducted studies demonstrated the influence of pH on the stability of model solutions (MS) during stress tests. In ampoules with solutions with a pH below 6.0, precipitation was observed during the first three days of observation, which indicates chemical instability and the formation of water-insoluble impurities. In ampoules with solutions with a pH of 8.0 and above, a color change from yellow to dark brown was observed, which indicates the occurrence of processes of destruction of the active components and further chemical interactions with the formation of potentially hazardous unidentified impurities in the drug. Table 3 Effect of pH of compositions on stability at 60±2°C (stress tests) N' composition Content pH Stability sodium hydroxide solution, g / l MP1 34.89 8.4 Unstable MR2 69.72 8.4 Unstable MRZ 87.23 8.4 Unstable MR1 34, 72 8.2 Unstable MR2 69.45 8.2 Unstable MRZ 86.81 8 , 2 Unstable MR1 34, 54 8, 0 Stable MR2 69, 09 8, 0 Stable MRZ 86, 36 8 , 0 Stable MR1 34, 09 7.4 Stable MR2 68, 18 7.4 Stable MRZ 85, 22 7.4 Stable MP1 33 , 84 7.0 Stable MP2 67, 67 7.0 Stable MP3 84, 59 7.0 Stable MP1 33.46 6.6 Stable MP2 66, 94 6.6 Stable MP3 83, 67 6.6 Stable MP1 32.06 6.0 Stable MP2 64, 13 6, 0 Stable MP3 80, 17 6.0 Stable MP1 31, 11 5.8 Unstable MP2 62 , 23 5.8 Unstable MP3 77, 78 5.8 Unstable MP1 28, 02 5.4 Unstable MP2 56, 03 5.4 Unstable MP3 70, 08 5.4 Unstable Thus, the obtained data show the predominant influence of pH on the stability of model solutions and the absence of dependence on the concentrations of active components in the studied ranges, which indicates the key influence of hydrolysis processes on the stability of the composition, and not the chemical interaction between the components in the studied pH range from 6.0 to 8.0. To further study the stability of the compositions after the stress test, we selected model solution N'2 (Example 13), containing succinic acid (10.0 wt.%), inosine (2.0 wt.%), nicotinamide (1.0 wt.%), sodium riboflavin mononucleotide (0.2 wt.%) and sodium hydroxide in the range of 6.41-6.91 wt.%, until the components were completely dissolved and the pH was established in the range from 6.0 to 8.0. The series of ampoules obtained in example 13 were subjected to thermal sterilization with water vapor under pressure in temperature range from 100±2 to 121±1°C with different exposure times from 2 to 8 minutes (Table 4). The stability of the compositions after temperature exposure was studied under accelerated aging conditions in a Binder KBF 240 climatic chamber for 6 months at a temperature of 40±1°C. The quantitative content of components and impurities was determined by HPLC under the following conditions: spectrophotometric detector, wavelength 254 nm, refractometric detector, Phenomenex Luna Phenyl-Hexyl chromatographic column, 250 mm long, 4.6 mm internal diameter, packed with 5 μm granulation sorbent, or similar; eluent flow rate 0.7 ml / min, column temperature 25DC; chromatography time is 30 min. The conditions for thermal sterilization of samples of the composition were considered acceptable (ICHQ3B Impurities in new drug products) for a safe medicinal product for intravenous administration if, after 6 months, the concentrations of active substances of the active components were at least 95.0 mass% of the initial value, the content of unidentified impurities did not exceed 2.0 mass%. The combined data of the experiment on the selection of optimal parameters for thermal sterilization of the model solution N2 are presented in Table 4. Table 4. Results of the experiment on selecting optimal parameters for thermal sterilization of model solution No. 2. W pH Temperature and sterilization time of model solution No. 3 of the experiment °C / min 121Ts / 8 121+1 / 2 116+2 / 2 112+2 / 4 108±2 / 6 104±2 / 8 100+2 / 8 8.0 + + + + + 7.8 + + + + + 7.6 + + + + + 7.4 + + + + + + 7.2 + + + + + + 7.0 + + + + + 6.8 + + + + + 6, 6 + + + + + 6.4 - + + + + + 6.2 + + + + + 6, 0 + + + + + Note: + the drug is stable when stored for 6 months, - the drug is not stable when stored for 6 months An analysis of the samples (Table 4) showed that at almost all sterilization temperatures above 116±2°C, precipitation, a greenish suspension, and a significant increase in hypoxanthine levels were observed during storage. A sterilization temperature of 121±1°C and an exposure time of 2 minutes produced stable compositions, but only within a narrow pH range of 7.2 to 7.4. This is extremely unfeasible, as it is difficult to obtain solutions with a pH close to the equivalence point in industrial production. Temperatures below 116°C enable the production of compositions stable for 6 months over a wide pH range of 6.0 to 8.0. Thus, during the studies, the optimal amount of the stabilizing agent and the parameters of thermal sterilization of the model composition N'2 were established, containing: succinic acid (10.0 wt.%), inosine (2.0 wt.%), nicotinamide (1.0 wt.%), sodium riboflavin mononucleotide (0.2 wt.%) and sodium hydroxide in the range of 6.41-69.1 wt.% until the components are completely dissolved and the pH is established in the range from 6.0 to 8.0 with thermal sterilization at a temperature from 100±2GC to 116±2°C and an exposure of 8 to 2 minutes. Taking into account the established parameters of the sterilization process, an assessment was further made of the possibility of using various pharmaceutically acceptable components from the selected group as stabilizers for the composition: sodium hydrogen carbonate (EP 9.0, 01 / 2017:0195, p.3585), sodium carbonate: (EP 9.0, 01 / 2017:0773, p.3570), sodium hydroxide (EP 9.0, 01 / 2017:0677, p.3836), TRIS (EP 9.0, 01 / 2017:1053, p.3851), ethanolamine (Handbook of pharmaceutical excipients 2010, p. 450; USP39-NF), diethanolamine (Handbook of pharmaceutical excipients 2010, p. 228; USP39-NF), meglumine (EP 9.0, 01 / 2017:2055, p.2992), L-arginine (EP 9.0, 01 / 2017:0806, p.1753) and their various combinations. For this purpose, solutions were prepared (Examples 15-20) with different contents of solubilizers in the previously established range of pH = 6.0-8.0, the process of thermal sterilization was carried out at borderline and intermediate values ​​in the temperature range of 100 and 116°C and the corresponding optimal exposure time from 8 to 2 minutes, and then the stability of the compositions was studied during long-term storage at temperature of 30 °C in the Binder climatic chamber; KBF 240 for two years. The shelf life of the composition was established using the HPLC method: if at the observation time point the concentration of active components was at least 95.0 mass% of the initial value, the content of unidentified impurities did not exceed 2.0 mass% and the drug remained sterile. Considering that inosine is easily hydrolyzed to poorly soluble hypoxanthine, we proposed sodium bicarbonate as the first mild stabilizing agent (Examples 15 and 16). Example 15. (sodium bicarbonate: series 15-100, 15-116). 50.0 L of water for injection, 10.0 kg of succinic acid, 0.5 kg of nicotinamide, 1.0 kg of inosine, 0.1 kg of riboflavin mononucleotide, and 13.76 kg of sodium bicarbonate are added to a 100 L apparatus with a stirrer until the components are completely dissolved and a pH of 6.0 is established. The volume of the solution is then brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules, and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 or 116°C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium bicarbonate 1376 mg (13.76 wt.%), water for injection up to 100.0 wt.%. Example 16. (sodium hydrogen carbonate: series 16-100, 16-116). 50.0 L of water for injection, 10.0 kg of succinic acid, 0.5 kg of nicotinamide, 1.0 kg of inosine, 0.1 kg of riboflavin mononucleotide, and 17.15 kg of sodium bicarbonate are loaded into a 100 L apparatus with a stirrer until the components are completely dissolved and the pH reaches 7.0. The volume of the solution is then brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 mL ampoules, and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium bicarbonate 1715 mg (17.15 wt.%), water for injection up to 100.0 wt.%. However, the preparation process according to Examples 15 and 16 resulted in intense foaming of the solution upon addition of sodium bicarbonate, particularly at the initial stage of dissolution due to the release of carbon dioxide. This significantly increases the preparation time and prevents the solution from achieving physiological pH values ​​of 7.3-7.4. An attempt to increase the amount of sodium bicarbonate above 17.1% by weight (Example 16) did not result in a further shift in pH above 7.0. Furthermore, precipitation of the composition components was observed due to exceeding their solubility limits. More alkaline solutions of the composition are preferable for clinical use, since one of the main The effect of the developed composition on the treatment of various syndromes is a decrease in blood pH (acidemia). The claimed method for producing compositions by additionally introducing one of the pharmaceutically acceptable components selected from the group consisting of sodium hydroxide, trisoxymethylaminomethane (TRIS), ethanolamine, diethanolamine, sodium carbonate, and meglumine as a stabilizing agent is illustrated by Examples 17-30. The use of sodium carbonate stabilizer instead of sodium bicarbonate makes it possible to achieve physiological pH values ​​(Examples 17 and 18), while the technological preparation process was also accompanied by abundant release of carbon dioxide and foaming. Example 17. (sodium carbonate: series 17-100, 17- 116). 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, and 11.22 kg of sodium carbonate are added to a 100 L apparatus with a stirrer until the components are completely dissolved and a pH of 6.0 is established. The volume of the solution is then brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules, and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 or 116°C with an exposure of 2 and 8 minutes, respectively. Each series of 10 ml ampoules contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium carbonate (11.66 wt.%), water for injection up to 100.0 wt.% Example 18. (sodium carbonate: series 18-100, 18-116) In a 100 L apparatus with a stirrer, 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, and 18.46 kg of sodium carbonate are loaded until the components are completely dissolved and a pH of 8.0 is established, then the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 or 116 ° C with an exposure of 2 and 8 minutes, respectively. Each series of 10 ml ampoules contains - succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium carbonate (18.46 wt.%), water for injection up to 100.0 wt.% Example 19. (sodium hydroxide: series 19-100, 19- 116) 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 6.41 kg of sodium hydroxide are loaded into a 100 l apparatus with a stirrer and mixed until the components are completely dissolved and a pH of 6.0 is established, and then the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 or 116 ° C with an exposure of 2 and 8 minutes, respectively. Each series of 10 ml ampoules contains - succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 641 mg (6.41 wt.%), water for injection up to 100.0 wt.% Example 20. (sodium hydroxide: series 20-100, 20- 116) 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, and 6.91 kg of sodium hydroxide are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and a pH of 8.0 is established. The volume of the solution is then brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules, and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100°C or 116°C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 691 mg (6.91 wt.%), water for injection up to 100.0 wt.%. Example 21. (TRIS: series 21-100, 21-116). 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, TRIS 19, 61 kg are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and a pH of 6.0 is established, then the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 ° C or 116 ° C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), TRIS 1961 mg (19.61 wt.%), water for injection up to 100.0 wt.%. Example 22. (TRIS: series 22-100, 22-116). 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, and 41.23 kg of TRIS are loaded into a 100 L apparatus with a stirrer until the components are completely dissolved and a pH of 8.0 is established. The volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 mL ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), TRIS 4123 mg (41.23 wt.%), water for injection up to 100.0 wt.%. Example 23. (ethanolamine: series 23-100, 23-116). In a 100 L apparatus with a stirrer, 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 9.8 kg of ethanolamine are loaded until the components are completely dissolved and the pH is 6.0, then the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), ethanolamine 980 mg (9.80 wt.%), water for injection up to 100.0 wt.%. Example 24. (ethanolamine: series 24-100, 24-116). 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 11.0 kg of ethanolamine are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and a pH of 8.0 is established, then the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), ethanolamine 1100 mg (11.0 wt.%), water for injection up to 100.0 wt.%. Example 25. (meglumine: series 25-100, 25-116) In a 100 L apparatus with a stirrer, 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, and 34.91 kg of meglumine are loaded until the components are completely dissolved and a pH of 8.0 is established, then the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Then the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 ° C or 116 ° C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains - succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), meglumine 3491 mg (34.91 wt.%), water for injection up to 100.0 wt. %. Example 26. (meglumine: series 26-100, 26-116) 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, and 31.32 kg of meglumine are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and the pH reaches 6.0. The resulting solution is then filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100°C or 116°C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), meglumine 3132 mg (31.32 wt.%), water for injection up to 100.0 wt.%. Example 27. (diethanolamine: series 27-100, 27-116) 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 20.83 kg of diethanolamine are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and to establish a pH of 8.0, then bring the volume of the solution to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 ° C or 116 ° C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains - succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), diethanolamine 2083 mg (20.83 wt.%), water for injection to 100.0 wt.%. Example 28. (diethanolamine: series 28-100, 28-116) 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, and 16.89 kg of sodium diethanolamine are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and a pH of 6.0 is established, then the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), diethanolamine 1689 mg (16.89 wt.%), water for injection up to 100.0 wt.%. Example 29. (L-arginine: series 29-100, 29-116). 50.0 L of water are loaded into a 100 L capacity apparatus with a stirrer for injections, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 28.0 kg of L-arginine until the components are completely dissolved and the pH is 6.0, then the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), L-arginine 2830 mg (28.3 wt.%), water for injection up to 100.0 wt.%. Example 30. (L-arginine: series 30-100, 30-116). 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, and 33.5 kg of L-arginine are loaded into a 100 L apparatus with a stirrer until the components are completely dissolved and a pH of 8.0 is established. The volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), L- arginine 3350 g (33.50 wt.%), water for injection up to 100.0 wt.%. The claimed method for producing compositions by additionally introducing several pharmaceutically acceptable components selected from the group consisting of sodium hydroxide, trisoxymethylaminomethane (TRIS), ethanolamine, diethanolamine, sodium carbonate, and meglumine as a stabilizing agent is illustrated in examples 31-91. Thus, the introduction of two components simultaneously is described in examples 31-60, three in examples 61-84, and four in examples 85-91. Example 31. (sodium hydroxide, TRIS: series 31-100, 31-116). 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 5.98 kg of sodium hydroxide and 5.54 kg of TRIS are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and a pH of 8.0 is established, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 598 mg (5.98 wt.%), TRIS 554 mg (5.54 wt.%), water for injection up to 100.0 wt.%. Example 32. (sodium hydroxide, TRIS: series 32-100, 32- 116). 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 1.81 kg of sodium hydroxide and 14.07 kg of TRIS are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and a pH of 6.0 is established, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 181 mg (1.81 wt.%), TRIS 1477 mg (14.77 wt.%), Ϊ water for injection up to 100.0 wt.%. Example 33. (sodium hydroxide, TRIS: series 33-100, 33- 116). 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 3.38 kg of sodium hydroxide and 12.93 kg of TRIS are loaded into a 100 l apparatus with a stirrer; the volume of the solution is brought to 100 l with water for injection until the components are completely dissolved and the pH reaches 7.4. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 ° C or 116 ° C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains - succinic acid 1000 mg (10.0 ass.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 883 mg (3.38 wt.%), TRIS 1293 mg (12.93 wt.%), water for injection up to 100.0 wt.%. Example 34. (sodium hydroxide, meglumine: series 34- 100, 34-116). 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 5.48 kg of sodium hydroxide and 7.19 kg of meglumine are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and the pH is established at 8.0, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 ° C or 116 ° C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 548 mg (5.48 wt.%), meglumine 719 mg (7.19 wt.%), water for injection up to 100.0 wt.%. Example 35. (sodium hydroxide, meglumine: series 35- 100, 35-116). In a 100 L apparatus with a stirrer, 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 3.39 kg of sodium hydroxide and 16.54 kg of meglumine are loaded until the components are completely dissolved and the pH is set to 7.0, the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with 0.22 μm pore diameter, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then thermally sterilized with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains - succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 339 mg (3.39 wt.%), meglumine 1654 mg (16.54 wt.%), water for injection up to 100.0 wt.%. Example 36. (sodium hydroxide, meglumine: series 36- 100 , 36 - 116 ). In a 100 L apparatus with a stirrer, 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 1.85 kg of sodium hydroxide and 22.28 kg of meglumine are loaded until the components are completely dissolved and the pH is established at 6.0, the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 185 mg (1.85 wt.%), meglumine 2228 mg (22.28 wt.%), water for injection up to 100.0 wt.%. Example 37. (sodium hydroxide, ethanolamine: series 37 - 100, 37 - 116). 50.0 l of water for injection, 10.0 kg of amber are loaded into an apparatus with a stirrer with a capacity of 100 acid, 1.0 kg nicotinamide, 2.0 kg inosine, 0.2 kg riboflavin mononucleotide, 5.07 kg sodium hydroxide, and 2.93 kg ethanolamine until the components are completely dissolved and a pH of 8.0 is established, the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules, and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100°C or 116°C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 507 mg (5.07 wt.%), ethanolamine 293 mg (2.93 wt.%), water for injection up to 100.0 wt.%. Example 38. (sodium hydroxide, ethanolamine: series 38-100, 38-116). 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 3.35 kg of sodium hydroxide and 5.22 kg of ethanolamine are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and the pH is established at 6.9, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 335 mg (3.35 wt.%), ethanolamine 522 mg (5.22 wt.%), water for injection up to 100.0 wt.%. Example 39. (sodium hydroxide, ethanolamine: series 39-100, 39-116). 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 1.68 kg of sodium hydroxide and 7.23 kg of ethanolamine are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and a pH of 6.0 is established, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 168 mg (1.68 wt.%), ethanolamine 723 mg (7.23 wt.%), water for injection up to 100.0 wt.%. Example 40. Trisodium hydroxide, L-arginine: series 40-100, 40-116). 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 4.93 kg of sodium hydroxide and 9.59 kg of L-arginine are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and the pH is established at 8.0, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 493 mg (4.93 wt.%), L-arginine 959 mg (9.59 wt.%), water for injection up to 100.0 wt.%. Example 41. (sodium hydroxide, L-arginine: series 41-100, 41-116). 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 3.57 kg of sodium hydroxide and 14.27 kg of L-arginine are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and a pH of 7.2 is established, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 ° C or 116 ° C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 357 mg (3.57 wt.%), L-arginine 1427 mg (14.27 wt.%), water for injection up to 100.0 wt.%. Example 42. (sodium hydroxide, L-arginine: series 42-100, 42-116). 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 1.9 kg of sodium hydroxide and 19.68 kg of L-arginine are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and After adjusting the pH to 6.0, the solution volume is brought to 100 liters with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 µm, poured into 10 ml ampoules, and sealed. The resulting series of ampoules are then subjected to thermal sterilization with steam under pressure at temperatures of 100°C or 116°C for exposures of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 190 mg (1.9 wt.%), L-arginine 1968 mg (19.68 wt.%), water for injection up to 100.0 wt.%. Example 43. (sodium hydroxide, diethanolamine: series 43-100, 43-116). 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 2.50 kg of sodium hydroxide and 13.29 kg of diethanolamine are loaded into a 100 L apparatus with a stirrer until the components are completely dissolved and a pH of 8.0 is established, the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter .0.22 μm, poured into 10 ml ampoules and sealed. Then the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 ° C or 116 ° C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains - succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 250 mg (2.5 0 wt.%), diethanolamine 1329 mg (13.29 wt.%), water for injection up to 100.0 Maqc.%. Example 44. (sodium hydroxide, diethanolamine: series 44-100, 44-116). A 100-liter apparatus with a stirrer is loaded with 50.0 liters of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 3.66 kg of sodium hydroxide, and 8.21 kg of diethanolamine until the components are completely dissolved and the pH reaches 6.9. The volume of the solution is brought to 100 liters with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10-ml ampoules, and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 366 mg (3.66 wt.%), diethanolamine 821 mg (8.21 wt.%), water for injection up to 100.0 wt.%. Example 45. (sodium hydroxide, diethanolamine: series 45-100, 45-116). 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 1.64 kg of sodium hydroxide and 12.56 kg of diethanolamine are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and a pH of 6.0 is established, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each ampoule contains 10 ml contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 164 mg (1.64 wt.%), diethanolamine 1256 mg (12.56 wt.%), water for injection up to 100.0 wt.%. Example 46. (TRIS, meglumine: series 46-100, 46- 116). 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 16.40 kg of TRIS, and 21.03 kg of meglumine are loaded into a 100 L apparatus with a stirrer until the components are completely dissolved and the pH reaches 8.0. The volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules, and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), TRIS 1640 mg (16.4 wt.%), meglumine 2103 mg (21.03 wt.%), water for injection up to 100.0 wt.%. Example 47. (TRIS, meglumine: series 47-100, 47- 116) . In a 100 L apparatus with a stirrer, 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 10.0 kg of TRIS and 17.72 kg of meglumine are loaded until the components are completely dissolved and a pH of 6.8 is established, the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Then the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 ° C or 116 ° C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains - succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), TRIS 1000 mg (10.0 wt.%), meglumine 1772 mg (17.72 wt.%), water for injection up to 100.0 wt.%. Example 48. (TRIS, meglumine: series 48-100, 48- 116). 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 5.02 kg of TRIS, and 23.29 kg of meglumine are loaded into a 100 L apparatus with a stirrer until the components are completely dissolved and a pH of 6.0 is established. The volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 mL ampoules, and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), TRIS 502 mg (5.02 wt.%), meglumine 2329 mg (23.29 wt.%), water for injection up to 100.0 wt.%. Example 49. (meglumine, L-arginine: series 49-100, 49- 116) . 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin are loaded into a 100 l apparatus with a stirrer. Mononucleotide, 23.53 kg of meglumine, and 10.92 kg of L-arginine are added until the components are completely dissolved and the pH reaches 8.0. The volume of the solution is then brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules, and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure at temperatures of 100°C or 116°C for exposures of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), meglumine 2353 mg (23.53 wt.%), L-arginine 1092 mg (10.92 wt.%), water for injection up to 100.0 wt.% Example 50 (meglumine, L-arginine: series 50-100, 50-116). 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 15.04 kg of meglumine and L-arginine are loaded into a 100 L apparatus with a stirrer. . 17, 07 kg until the components are completely dissolved and the pH is 7.5, bring the volume of the solution to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 ° C or 116 ° C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains - succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), meglumine 1504 mg (15.04 mass L), L-arginine 1707 mg (17.07 mass%), water for injection up to 100.0 mass% Example 51 (meglumine, L-arginine: series 51-100, 51-116). 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 8.71 kg of meglumine, and 20.18 kg of L-arginine are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and a pH of 6.0 is established; the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules, and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100°C or 116°C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), meglumine 871 mg (8.71 wt.%), L-arginine 2018 mg (20.18 wt.%), water for injection up to 100.0 wt.%. Example 52. (meglumine, ethanolamine: series 52-100, 52-116). 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 20.36 kg of meglumine and 4.59 kg of ethanolamine are loaded into a 100 L apparatus with a stirrer until the components are completely dissolved and a pH of 8.0 is established, the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in temperature ranges of 100°C or 116°C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), meglumine 2036 mg (20.36 wt.%), ethanolamine 459 mg (4.59 wt.%), water for injection up to 100.0 wt.%. Example 53. (meglumine, ethanolamine: series 53-100, 53-116). 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 15.72 kg of meglumine and 5.46 kg of ethanolamine are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and a pH of 7.0 is established, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), meglumine 1572 mg (15.72 wt.%), ethanolamine 546 mg (5.46 wt.%), water for injection up to 100.0 wt.%. Example 54. (meglumine, ethanolamine: series 54-100, 54-116). 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 6.33 kg of meglumine and 7.82 kg of ethanolamine are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and the pH is set to 6.0. The solution volume is brought to 100 liters with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 µm, poured into 10 ml ampoules, and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure at temperatures of 100°C or 116°C for exposures of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), meglumine 633 mg (6.33 wt.%), ethanolamine 782 mg (7.82 wt.%), water for injection up to 100.0 wt.%. Example 55. (sodium carbonate, sodium hydroxide: series 55-100, 55a-116). In a 100 L apparatus with a stirrer, 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 4.11 kg of sodium carbonate and 4.04 kg of sodium hydroxide are loaded until the components are completely dissolved and the pH is established at 6.0, the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium carbonate 411 mg (4.11 wt.%), sodium hydroxide 404 mg (4.04 wt.%), water for injection up to 100.0 wt.%. Example 56. (sodium carbonate, sodium hydroxide: series 56-100, 56-116). In a 100 L apparatus with a stirrer, 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 8.82 kg of sodium carbonate and 3.25 kg of sodium hydroxide are loaded until the components are completely dissolved and the pH is established at 7.2, the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The obtained series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium carbonate 882 mg (8.82 wt.%), sodium hydroxide 325 mg (3.25 wt.%), water for injection up to 100.0 wt.%. Example 57. (sodium carbonate, sodium hydroxide: series 57-100, 57-116). In a 100 L apparatus with a stirrer, 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 14.14 kg of sodium carbonate and 1.62 kg of sodium hydroxide are loaded until the components are completely dissolved and a pH of 8.0 is established, the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter ! 0.22 µm, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure at temperatures of 100°C or 116°C for exposures of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium carbonate 1414 mg (14.14 wt.%), sodium hydroxide 162 mg (1.62 wt.%), water for injection up to 100.0 wt.%. Example 58. (sodium carbonate, meglumine: series 58- 100, 58-116). 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 4.86 kg of sodium carbonate and 17.59 kg of meglumine are loaded into a 100 L apparatus with a stirrer until the components are completely dissolved and a pH of 6.0 is established, the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 ° C or 116 ° C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium carbonate 486 mg (4.86 wt.%), meglumine 1759 mg (17.59 wt.%), water for injection up to 100.0 wt.%. Example 59. (sodium carbonate, meglumine: series 59d- 100, 59д116). In a 100 l apparatus with a stirrer, 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 8.71 kg of sodium carbonate, 15.74 kg of meglumine are loaded until the components are completely dissolved and the pH is set to 7.1, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with 0.22 μm pore diameter, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 ° C or 116 ° C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains - succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium carbonate 874 mg (8.71 wt.%), meglumine 1574 mg (15.74 wt.%) ^ water for injection up to 100.0 wt.%. Example 60. (sodium carbonate, meglumine: series 60- 100, 60-116). 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 14.70 kg of sodium carbonate, and 7.11 kg of meglumine are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and a pH of 8.0 is established, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium carbonate 1470 mg (14.70 wt.%), meglumine 711 mg (7.11 wt.%), water for injection up to 100.0 wt.%. Example 61. (sodium hydroxide, meglumine, TRIS: series 61-100, 61-116) 50.0 l of water for injection, 10.0 kg of amber acid, 1.0 kg nicotinamide, 2.0 kg inosine, 0.2 kg riboflavin mononucleotide, 2.60 kg sodium hydroxide and 11.08 kg meglumine, 12.59 kg TRIS until the components are completely dissolved and a pH of 8.0 is established, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 260 mg (2.6 wt.%), meglumine, 1108 mg (11.08 wt.%), TRIS 1259 mg (12.59 wt.%) water for injection up to 100.0 wt.%. Example 62. (sodium hydroxide, meglumine, TRIS: series 62-100, 62-116) In an apparatus with a stirrer with a capacity of 100 l, 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 3.62 kg of sodium hydroxide and 11.76 kg of meglumine, 2.60 kg of TRIS are loaded until the components are completely dissolved and the pH is established at 7.1, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure at temperatures of 100°C or 116°C with an exposure time of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), and nicotinamide 100 mg. (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 362 mg (3.62 wt.%), meglumine 1176 mg (11.76 wt.%), TRIS 260 mg (2.6 wt.%), water for injection up to 100.0 wt.%. Example 63. (sodium hydroxide, meglumine, TRIS: series 63-100, 63-116) In an apparatus with a stirrer with a capacity of 100 l, 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 1.3 kg of sodium hydroxide, 11.3 kg of TRIS and 8.47 kg of meglumine are loaded until the components are completely dissolved and the pH is established at 6.0, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure at temperatures of 100°C or 116°C with an exposure time of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), and nicotinamide 100 mg. (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 130 mg (1.3 wt.%), meglumine ISO mg (11.3 wt.%), TRIS 847 mg (8.47 wt.%), water for injection up to 100.0 wt.%. Example 64. (sodium hydroxide, ethanolamine, TRIS: series 64-100, 64-116). In a 100 L apparatus with a stirrer, 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 3.98 kg of sodium hydroxide and 4.19 kg of ethanolamine, 1.80 kg of TRIS are loaded until the components are completely dissolved and a pH of 8.0 is established, the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 µm, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 398 mg (3.98 wt.%), ethanolamine 419 mg (4.19 wt.%), TRIS 180 mg (1.80 wt.%) water for injection up to 100.0 wt.%. Example 65. (sodium hydroxide, ethanolamine, TRIS: series 65-100, 65-116). In an apparatus with a stirrer with a capacity of 100 l, 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 3.08 kg of sodium hydroxide and 3.48 kg of ethanolamine, 4.88 kg of TRIS are loaded until the components are completely dissolved and the pH is established at 7.1, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100°C or 116°C with an exposure time of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 308 mg (3.08 wt.%), ethanolamine 348 mg (3.48 wt.%), TRIS 488 mg (4.88 wt.%), water for injection up to 100.0 wt.%. Example 66. (sodium hydroxide, ethanolamine, TRIS: series 66-100, 66-116). In an apparatus with a stirrer with a capacity of 100 l, 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 1.54 kg of sodium hydroxide and 6.88 kg of ethanolamine, 1.13 kg of TRIS are loaded until the components are completely dissolved and the pH is established at 6.0, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100°C or 116°C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 1.54 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 154 mg (1.54 wt.%), ethanolamine 688 mg (6.88 wt.%), TRIS 113 mg (1.13 wt.%), water for injection up to 100.0 wt. % . Example 67. (sodium hydroxide, meglumine, L-arginine: series 67-100, 67-116). In an apparatus with a stirrer with a capacity of 100 l, 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 4.37 sodium hydroxide, 7.63 kg of meglumine and 4.90 kg of L-arginine are loaded until the components are completely dissolved and the pH is established at 8.0, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in temperature ranges of 100 °C. or 116°C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 437 mg (4.37 wt.%), meglumine 763 mg (7.63 wt.%), L-arginine 490 mg (4.90 wt.%), water for injection up to 100.0 wt.%. Example 68. (sodium hydroxide, meglumine, L-arginine: series 68-100, 68-116) In an apparatus with a stirrer with a capacity of 100 L, 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 3.28 kg of sodium hydroxide, 6.16 kg of meglumine and 9.82 kg of L-arginine are loaded until the components are completely dissolved and the pH is established at 7.0, the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 328 mg (3.28 wt.%), meglumine 616 mg (6.16 wt.%).%), L-arginine 982 mg (9.82 wt.%), water for injection up to 100.0 wt.%. Example 69. (sodium hydroxide, meglumine, Li - arginine: series 69-100, 69-116) 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 2.20 kg of sodium hydroxide are loaded into an apparatus with a stirrer with a capacity of 100 l. 10.0 kg of meglumine and 9.44 kg of L-arginine are added until the components are completely dissolved and the pH reaches 6.0. The solution is then diluted to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 µm, poured into 10 ml ampoules, and sealed. The resulting series of ampoules are then subjected to thermal sterilization with steam under pressure at temperatures of 100°C or 116°C for exposures of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 220 mg (2.20 wt.%), meglumine 1000 mg (10.0 wt.%), L-arginine 944 mg (9.44 wt.%), water for injection up to 100.0 wt.%. Example 70. (TRIS, meglumine, L-arginine: series 70- 100, 70-116). In a 100 L apparatus with a stirrer, 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 15.8 kg of TRIS, 6.33 kg of meglumine and 14.60 kg of L-arginine are loaded until the components are completely dissolved and the pH is established at 8.0, the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), TRIS 1580 mg (15.8 wt.%), meglumine (6.33 wt.%), L-arginine 633 mg (14.60 wt.%), water for injection up to 100.0 wt.%. Example 71. (TRIS, meglumine, L-arginine: series 71- 100, 71-116). In a 100 L apparatus with a stirrer, 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 11.08 kg of TRIS, 10.40 kg of meglumine and 5.76 kg of L-arginine are loaded until the components are completely dissolved and a pH of 7.0 is established. The volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The obtained series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains - succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), TRIS 1108 mg (11.08 wt.%), meglumine 1040 mg (10.40 wt.%), L-arginine 576 mg (5.76 wt.%), water for injection up to 100.0 wt. %. Example 72. (TRIS, meglumine, L-arginine: series 72- 100, 72-116) 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 6.11 kg of TRIS, 10.20 kg of meglumine and 10.20 kg of L-arginine are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and a pH of 6.0 is established, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Then the resulting series The ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains - succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), TRIS 611 mg (6.11 wt.%), meglumine 1020 mg (10.20 wt.%), L-arginine 1020 mg (10.20 wt.%), water for injection up to 100.0 wt. %. Example 73. (TRIS, meglumine, ethanolamine: series 73- 100, 73-116). A 100 L apparatus with a stirrer is loaded with 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 13.4 kg of TRIS, 4.98 kg of meglumine and 5.87 kg of ethanolamine until the components are completely dissolved and the pH is established at 8.0, the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), TRIS 134 mg (13.4 wt.%), meglumine 498 mg (4.98 wt.%), ethanolamine 587 mg (5.87 wt.%), water for injection up to 100.0 wt.%. Example 74. (TRIS, meglumine, ethanolamine: series 74- 100, 74-116). 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of Nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin ononucleotide, 10.42 kg of TRIS, 8.90 kg of eglumine, and 2.65 kg of ethanolamine are added until the components are completely dissolved and the pH is adjusted to 6.9. The volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules, and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure at temperatures of 100°C or 116°C with an exposure time of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), TRIS 1042 mg (10.42 wt.%), meglumine 890 mg (8.90 wt.%), ethanolamine 265 mg (2.65 wt.%), water for injection up to 100.0 wt.%. Example 75. (TRIS, meglumine, ethanolamine: series 75- 100, 75-116) 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 3.96 kg of TRIS, 11.68 kg of meglumine and 4.16 kg of ethanolamine are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and a pH of 6.0 is established, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 mass%), riboflavin mononucleotide 20 mg (0.2 mass%), TRIS 396 mg (3.96 mass%), meglumine 1168 mg (11.68 mass%), ethanolamine 416 mg (4.16 mass%), water for injection up to 100.0 mass%. Example 76. (TRIS, ethanolamine, L-arginine: series 76-100, 76-116). In a 100-liter apparatus with a stirrer, 50.0 liters of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 19.26 kg of TRIS, 2.99 kg of ethanolamine and 8.78 kg of L-arginine are loaded until the components are completely dissolved and a pH of 8.0 is established, the volume of the solution is brought to 100 liters with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The obtained series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100°C or 116°C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains - succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), TRIS 1926 mg (19.26 wt.%), ethanolamine 299 mg (2.99 wt.%), L-arginine 878 mg (8.78 wt.%), water for injection up to 100.0 wt. %. Example 77. (TRIS, ethanolamine, L-arginine: series 77-100, 77-116). In a 100-liter apparatus with a stirrer, 50.0 liters of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 11.23 kg of TRIS, 1.90 kg of ethanolamine, and 9.10 kg of L-arginine are loaded until the components are completely dissolved and a pH of 6.9 is established. The volume of the solution is brought to 100 liters with water for injection. The resulting solution is filtered through A sterilizing filter with a pore diameter of 0.22 µm is poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure at temperatures of 100°C or 116°C for exposures of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), TRIS 1123 mg (11.23 wt.%), ethanolamine 190 mg (1.90 wt.%), L-arginine 910 mg (9.10.0 wt.%), water for injection up to 100.0 wt.%. Example 78. (TRIS, ethanolamine, L-arginine: series 78-100, 78-116). In a 100 L apparatus with a stirrer, 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 5.62 kg of TRIS, 6.26 kg of ethanolamine and 2.08 kg of L-arginine are loaded until the components are completely dissolved and a pH of 6.0 is established, the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The obtained series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100°C or 116°C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), TRIS 562 mg (5.62 wt.%), ethanolamine 626 mg (6.26 wt.%), L-arginine 208 mg (2.08 wt.%), water for injection up to 100.0 wt.%. Example 79. (meglumine, ethanolamine, L-arginine: series 79-100, 79-116). In an apparatus with a stirrer with a capacity of 100 l, 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 19.93 kg of meglumine, 3.98 kg of ethanolamine and 2.27 kg of L-arginine are loaded until the components are completely dissolved and the pH is established at 8.0, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), meglumine 1993 mg (19.93 wt.%), ethanolamine 398 mg (3.98 wt.%), L-arginine 227 mg (2.27 wt.%).%), water for injection up to 100.0 mass. % . Example 80. (meglumine, ethanolamine, L-arginine: series 80-100, 80-116). In an apparatus with a stirrer with a capacity of 100 l, 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 16.53 kg of meglumine, 2.58 kg of ethanolamine and 7.24 kg of L-arginine are loaded until the components are completely dissolved and the pH is established at 6.7, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in temperature ranges of 100°C. or 116°C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), meglumine 1653 mg (16.53 wt.%), ethanolamine 258 mg (2.58 wt.%), L-arginine 427 mg (7.24 wt.%), water for injection up to 100.0 wt.%. Example 81. (meglumine, ethanolamine, L-arginine: series 81-100, 81-116). In a 100 L apparatus with a stirrer, 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 7.88 kg of meglumine, 4.28 kg of ethanolamine and 8.71 kg of L-arginine are loaded until the components are completely dissolved and the pH is 6.0, the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure at temperatures of 100°C or 116°C with an exposure time of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), and nicotinamide 100 mg. (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), meglumine 788 mg (7.88 wt.%), ethanolamine 428 mg (4.28 wt.%), L-arginine 871 mg (8.71 wt.%), water for injection up to 100.0 wt.%. Example 82. (meglumine, diethanolamine, TRIS: series 82-100, 82-116). 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 19.4 kg of meglumine are loaded into a 100 l apparatus with a stirrer, 3.17 kg of diethanolamine and 12.03 kg of TRIS are added until the components are completely dissolved and a pH of 8.0 is reached. The volume of the solution is then diluted to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 µm, poured into 10 ml ampoules, and sealed. The resulting series of ampoules are then subjected to thermal sterilization with steam under pressure at temperatures of 100°C or 116°C for exposures of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), meglumine 194 mg (19.4 wt.%), diethanolamine 317 mg (3.17 wt.%), TRIS 1203 mg (12.03 wt.%), water for injection up to 100.0 wt.%. Example 83. (meglumine, diethanolamine, TRIS: series 83-100, 83-116). In a 100-liter apparatus with a stirrer, 50.0 liters of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, meglumine 1:6.3 kg, diethanolamine 6.97 kg and TRIS 2.89 kg are loaded until the components are completely dissolved and the pH is set to 7.1, the volume of the solution is brought to 100 liters with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), meglumine 163 mg (16.3 wt.%), diethanolamine 697 mg (6.97 mass%), TRIS 289 g (2.89 mass%), water for injection up to 100.0 mass%. Example 84. (meglumine, diethanolamine, TRIS: series 84-100, 84-116). In a 100 L apparatus with a stirrer, 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 6.07 kg of meglumine, 7.18 kg of diethanolamine and 7.47 kg of TRIS are loaded until the components are completely dissolved and a pH of 6.0 is established, the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The obtained series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), meglumine 607 mg (6.07 wt.%), diethanolamine 718 mg (7.18 wt.%), TRIS 747 mg (7.47 wt.%), water for injection up to 100.0 wt.%. Example 85. (sodium hydroxide, meglumine, ethanolamine, L-arginine: series 85-100, 85-116). In an apparatus with a stirrer with a capacity of 100 l, 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 3.39 kg of sodium hydroxide, 10.57 kg of meglumine, 1.18 kg of ethanolamine and 3.35 kg of L-arginine are loaded until the components are completely dissolved and the pH is established at 8.0, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains - succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 339 mg (3.39 wt.%), meglumine 1057 mg (10.57 wt.%), ethanolamine 118 mg (1.18 wt.%), L-arginine 335 mg (3.35 wt.%), water for injection up to 100.0 wt.%. Example 86. (sodium hydroxide, meglumine, ethanolamine, L-arginine: series 86-100, 86-116). In an apparatus with a stirrer with a capacity of 100 L, 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 1.54 kg of sodium hydroxide, 7.62 kg of meglumine, 2.62 kg of ethanolamine and 97 kg of L-argininab are loaded until the components are completely dissolved and a pH of 6.0 is established, the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 154 mg (1.54 wt.%), meglumine 76 |2 mg (7.62 wt.%), ethanolamine 262 mg (2.62 wt.%), b-arginine 697 mg (6.97 wt.%), water for injection up to 100.0 wt.%. Example 87. (sodium hydroxide, meglumine, ethanolamine, TRIS: series 87-100, 87-116). In an apparatus with a stirrer with a capacity of 100 l, 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 2.62 kg of sodium hydroxide, 5.70 kg of meglumine, 4.18 kg of ethanolamine and 3.17 kg of TRIS are loaded until the components are completely dissolved and a pH of 8.0 is established, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature range of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 262 mg (2.62 wt.%), meglumine 570 mg (5.70 wt.%), ethanolamine 418 mg (4.18 wt.%), TRIS 317 mg (3.17 wt.%), water for injection up to 100.0 wt.%. Example 88. (sodium hydroxide, meglumine, ethanolamine, TRIS: series 88-100, 88-116). In a 100 L apparatus with a stirrer, 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 1.54 kg of sodium hydroxide, 7.61 kg of meglumine, 2.36 kg of ethanolamine and 5.45 kg of TRIS are loaded until the components are completely dissolved and a pH of 6.0 is established, the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Then the resulting series The ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), sodium hydroxide 154 mg (1.54 wt.%), meglumine 761 mg (7.61 wt.%), ethanolamine 236 mg (2.36 wt.%), TRIS 545 mg (5.45 wt.%), water for injection up to 100.0 wt.%. Example 89. (meglumine, ethanolamine, diethanolamine, TRIS: series 89-100, 89-116). In a 100 l apparatus with a stirrer, 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 7.45 kg of meglumine, 3.80 kg of ethanolamine, 3.98 kg of diethanolamine, 9.96 kg of TRIS are loaded until the components are completely dissolved and the pH is set to 8.0, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), meglumine 745 mg (7.45 wt.%), ethanolamine 380 mg (3.80 wt.%), diethanolamine 398 mg (3.98 wt.%), TRIS 996 mg (9.96 wt.%), water for injection up to 100.0 wt.%. Example 90. (meglumine, ethanolamine, diethanolamine, TRIS: series 90-100, 90-116). In the apparatus with a stirrer capacity 100 l are loaded with 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 10.00 kg of meglumine, 2.50 kg of ethanolamine, 2.50 kg of diethanolamine, 15.1 kg of TRIS until the components are completely dissolved and the pH is established to 8.0, the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), meglumine 1000 mg (10.0 wt.%), ethanolamine 250 mg (2.50 wt.%), diethanolamine 250 mg (2.50 wt.%), TRIS 151 mg (15.1 wt.%), water for injection up to 100.0 wt.%. Example 91. (meglumine, ethanolamine, diethanolamine, TRIS: series 91-100, 91-116). In a 100 L apparatus with a stirrer, 50.0 L of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 16.53 kg of meglumine, 1.55 kg of ethanolamine, 2.67 kg of diethanolamine, 3.07 kg of TRIS are loaded until the components are completely dissolved and the pH is 6.0, the volume of the solution is brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the obtained series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature range of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), meglumine 1653 mg (16.53 wt.%), ethanolamine 155 mg (1.55 wt.%), diethanolamine 267 mg (2.67 wt.%), TRIS 307 mg (3.07 wt.%), water for injection up to 100.0 wt.%. Specific implementations of the claimed method are described in Examples 92-96. When studying compositions using pharmacopoeial sodium bicarbonate, physiologically acceptable pH values ​​were achieved only in combination with other stabilizers added in an equimolar ratio to succinic acid. The maximum achievable pH values ​​did not exceed 7.3-7.5 (Examples 92-96). Further addition of sodium bicarbonate resulted in precipitation of the combination components. Example 92. (sodium hydroxide, sodium bicarbonate: series 92-100, 92-116). In an apparatus with a stirrer with a capacity of 100 l, 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 6.77 kg of sodium hydroxide and 2.05 kg of sodium bicarbonate are loaded until the components are completely dissolved and the pH is established at 7.4, then the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100°C or 116°C with an exposure time of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 mass%), inosine 200 mg (2.0 mass%), nicotinamide 100 mg (1.0 mass%), riboflavin mononucleotide 20 mg (0.2 mass%), sodium hydroxide 598 mg (5.98 mass%), sodium hydrogen carbonate 205 mg (2.05 mass%), water for injection up to 100.0 mass%. Example 93. (meglumine, sodium bicarbonate: series 93-100, 93-116). 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 33.06 kg of meglumine and 2.49 kg of sodium hydrogen carbonate are loaded into a 100 l apparatus with a stirrer until the components are completely dissolved and the pH is established to 7.3, then the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains: succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), meglumine 3306 mg (33.06 wt.%), sodium bicarbonate 249 mg (2.49 wt.%), water for injection up to 100.0 wt.%. Example 94. (TRIS, sodium bicarbonate: series 94- 100, 94 - 116). In a 100 l apparatus with a stirrer, 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 20.52 kg of TRIS and 2.90 kg of sodium bicarbonate are loaded until the components are completely dissolved and the pH is set to 6.7, then the volume of the solution is brought to 100 l with water for injection. The resulting solution is filtered through a sterilizing filter with 0.22 μm pore diameter, poured into 10 ml ampoules and sealed. The resulting series of ampoules are then thermally sterilized with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), TRIS 2052 mg (20.52 wt.%), sodium bicarbonate 290 mg (2.90 wt.%), water for injection up to 100.0 wt.%. Example 95. (TRIS, sodium bicarbonate: series 95- 100, 95-116). In a 100 l apparatus with a stirrer, 50.0 l of water for injection, 10.0 kg of succinic acid, 1.0 kg of nicotinamide, 2.0 kg of inosine, 0.2 kg of riboflavin mononucleotide, 20.52 kg of TRIS and 0.10 kg of sodium bicarbonate are loaded until the components are completely dissolved and the pH is set to 6.4, then the volume of the solution is brought up to the required level with water for injection. :up to 100 l. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules and sealed. Next, the resulting series of ampoules are subjected to thermal sterilization with water vapor under pressure in the temperature ranges of 100 °C or 116 °C with an exposure of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), TRIS 2052 mg (20.52 wt.%), sodium bicarbonate 10 mg (0.10.0 wt.%), water for injection up to 100.0 wt.%. Example 96. (meglumine, sodium hydroxide, sodium bicarbonate: series 96-100, 96-116). 50.0 l of water for injection, 10.0 kg of Succinic acid, 1.0 kg nicotinamide, 2.0 kg inosine, 0.2 kg riboflavin mononucleotide, 16.53 kg meglumine, 3.39 kg sodium hydroxide, and 2.37 kg sodium bicarbonate are mixed until the components are completely dissolved and the pH reaches 7.3. The solution is then brought to 100 L with water for injection. The resulting solution is filtered through a sterilizing filter with a pore diameter of 0.22 μm, poured into 10 ml ampoules, and sealed. The resulting series of ampoules are then subjected to thermal sterilization with water vapor under pressure at temperatures of 100 °C or 116 °C with an exposure time of 2 and 8 minutes, respectively. Each 10 ml ampoule contains succinic acid 1000 mg (10.0 wt.%), inosine 200 mg (2.0 wt.%), nicotinamide 100 mg (1.0 wt.%), riboflavin mononucleotide 20 mg (0.2 wt.%), meglumine 1653 mg (16.53 wt.%), sodium hydroxide 339 mg (3.39 wt.%), bicarbonate 237 mg (2.37 wt.%), water for injection up to 100.0 wt.%. Table 5 Study of the influence of solution pH and sterilization mode on the stability of compositions with different stabilizer compositions Example Batch number pH of solution Observation period, months 0 3 6 12 18 24 15-100 6, 0 + + + + + + 15 15-116 6.0 + + + + + + 16-100 7.0 + + + + + + 16 16-116 7.0 + + + + + + 17-100 6.0 + + + + + + 17 17-116 6.0 + + + + + + 18-100 8.0 + + + + + + 18 18-116 8.0 + + + + + + 19-100 6, 0 + + + + + + 19 19-116 6, 0 + + + + + + 20-100 8.0 + + + + + + 20-116 8.0 + + + + + + 21-100 6.0 + + + + + + 21-116 6.0 + + + + + + 22-100 8 , 0 + + + + + + 22-116 8.0 + + + + + + 23-100 6.0 + + + + + + 23-116 6.0 + + + + + + 24-100 8.0 + + + + + + 24-116 8.0 + + + + + + 25-100 8,0 + + + + + + 25-116 8,0 + + + + + + 26-100 6,0 + + + + + + 26-116 6,0 + + + + + + 27-100 8,0 + + + + + + 27-116 8,0 + + + + + + 28-100 6,0 + + + + + + 28-116 6,0 + + + + + + 29-100 6,0 + + + + - - 29-116 6, 0 + + - - - - 30-100 8,0 + + + + + + 30-116 8,0 + + + + + + 31-100 8,0 + + + + + + 31-116 8,0 + + + + + + 32-100 6,0 + + + + + + 32-116 6,0 + + + + + + 33-100 7,4 + + + + + + 33-116 7,4 + + + + + + 34-100 8,0 + + + + + + 34-116 8, 0 + + + + + + 35-100 7,0 + + + + + + 35-116 7,0 + + + + + + 36-100 6 , 0 + + + + + + -116 6, 0 + + + + + +-100 8 , 0 + + + + + +-116 8,0 + + + + + +-100 6,9 + + + + + +-116 6, 9 + + + + + +-100 6, 0 + + + + + +-116 6, 0 + + + + + +-100 8, 0 + + + + - --116 8, 0 + + - - - --100 7,2 + + + + --116 7,2 + + + + + --100 6,0 + + + + - --116 6,0 + + + + - --100 8 , 0 + + + + + +-116 8,0 + + + + + +-100 6,9 + + + + + +-116 6,9 + + + + + +-100 6,0 + + + + + +-116 6,0 + + + + + +-100 8,0 + + + + + +-116 8,0 + + + + + +-100 6,8 + + + + + +-116 6,8 + + + + + +-100 6,0 + + + 4 + +-116 6,0 + + + + + +-100 8,0 + + + + - --116 8,0 + + + - - --100 7,5 + + + + - --116 7,5 + + + + - --100 6 , 0 + + + + + --116 6, 0 + + + + - --100 8, 0 + + + + + +-116 8,0 + + + + + + 53-100 7, 0 + + + + + + 53-116 7,0 + + + + + + 54-100 6,0 + + + + + + 54-116 6,0 + + + + + + 55-100 6,0 + + + + + + 55-116 6, 0 + + + + + + 56-100 7,2 + + + + + + 56-116 7,2 + + + + + 57-100 8,0 + + + + + + 57-116 8, 0 + + + + + + 58-100 6.0 + + + + + + 58-116 6, 0 + + + + + + 59-100 V, 1 + + + + + + 59-116 7, 1 + + + + + + 60-100 8.0 + + + + + + 60-116 8.0 + + + + + + 61-100 8.0 + + + + + + 61-116 8.0 + + + + + + 62-100 7 , 1 + + + + + + 62-116 V, 1 + + + + + + 63-100 6.0 + + + + + + 63-116 6.0 + + + + + + 64-100 8, 0 + + + + + + 64-116 8.0 + + + + + + 65-100 7, 1 + + + + + + 65-116 V, 1 + + + + + + 66-100 6.0 + + + + + + 66-116 6, 0 + + + + + + 67-100 8.0 + + + + - - 67-116 8.0 + + + - - - 68-100 7, 0 + + + + - - 68-116 7.0 + + + - - - 69-100 6, 0 + + + + - - 69-116 6, 0 + + + + - - 70-100 8.0 + + + + - - 70 70-116 8, 0 + + + - - - 71-100 7.0 + + + + - - 71 71-116 7 , 0 + + + - - - 72-100 6, 0 + + + + - - 72 72-116 6,0 + + + - - - 73-100 8,0 + + + + + + 73 73-116 8,0 + + + + + + 74-100 6,9 + + + + + + 74 74-116 6,9 + + + + + + 75-100 6,0 + + + + + + 75 75-116 6,0 + + + + + + 76-100 8,0 + + + - - - 76 76-116 8, 0 + + - - - - 77-100 6, 9 + + + + - - 77 77-116 6,9 + + + - - - 78-100 6, 0 + + + + - - 78 78-116 6,0 + + + - - 79-100 8, 0 + + + - - - 79 79-116 8,0 + + - - - - 80-100 6,7 + + + - - - 80 80-116 6,7 + + - - - - 81-100 6, 0 + + + + - - 81 81-116 6, 0 + + + - - - 82-100 8,0 + + + + + + 82 82-116 8,0 + + + + + + 83-100 7,1 + + + + + + 83 83-116 7,1 + + + + + + 84-100 6, 0 + + + + + + 84 84-116 6,0 + + + + + + 85-100 8, 0 + + + + - - 85 85-116 8,0 + + + - - - 86-100 6,0 + + + + - - 86 86-116 6, 0 + + + - - - 87-100 8,0 + + + + + + 87 87-116 8,0 + + + +: + + 88-100 6,0 + + + + + + 88 88-116 6,0 + + + + + + 89-100 8 , 0 + + + + + + 89 89-116 8,0 + + + + + + 90-100 8,0 + + + + + + 90 90-116 8,0 + + + + + + 91-100 6,0 + + + + + + 91 91-116 6 , 0 + + + + + + 92-100 7,4 + + + + + + 92 92-116 7,4 + + + + + + 93-100 7,3 + + + + + + 93 93-116 7,3 + + + + + + 94-100 6,7 + + + + + + 94 94-116 6.7 + + + + + + 95-100 6.4 + + + + + + 95 95-116 6.4 + + + + + + 96-100 7.3 + + + + + + 96 96-116 7.3 + + + + + + When studying the stability of compositions (Table 5), with different compositions of stabilizing agents, it was established: 1). The compositions obtained according to examples 29, 40-42, 49-51, 67-72, 76-81, 85-86, which included L-arginine, did not withstand long-term storage for 2 years at a temperature of 30 °C. In the samples, which included arginine as a stabilizing agent, a significant amount of unidentified impurities is formed during storage, the presence of which reduces the safety of the use of the parenteral drug, and, therefore, These compositions cannot be used in medical practice. 2). the possibility of using sodium hydroxide, sodium carbonate, meglumine, TRIS, ethanolamine, diethanolamine, sodium bicarbonate and their various combinations as stabilizing agents for obtaining drugs for intravenous administration with physiological pH values ​​and stable during storage for more than 2 years. Thus, the claimed method makes it possible to obtain a stabilized pharmaceutical composition in the form of an aqueous solution, prevent the destruction of active components, and significantly reduce the likelihood of contamination by microorganisms during the preparation of the drug, which increases its safety while maintaining therapeutic effectiveness.

Claims

CLAUSES OF THE INVENTION 1. A method for obtaining a stabilized pharmaceutical composition in the form of an aqueous solution containing succinic acid, inosine, nicotinamide, sodium riboflavin mononucleotide as active components by dissolving them in water followed by sterilizing filtration, characterized in that one or more pharmaceutically acceptable components selected from the group consisting of sodium hydroxide, trisoxymethylaminomethane (TRIS), ethanolamine, diethanolamine, sodium carbonate, meglumine are additionally introduced into the composition as a stabilizing agent until a stable solution is obtained with a pH value in the range from 6.0 to 8.0 with the following ratio of components, mass %: succinic acid 5.00-12.50 inosine 1.00-2.40 nicotinamide 0.50-1.20 sodium riboflavin mononucleotide 0.10-0.24 stabilizing agent 3.21-51.30 water to 100.0%, and additionally carry out thermal sterilization of the solution at a temperature of 100°C and an exposure time of 8 minutes to 116°C and an exposure time of 2 minutes.

2. A method for producing a stabilized pharmaceutical composition according to paragraph 1, characterized in that sodium bicarbonate is introduced into the composition as a stabilizing agent until a stable solution is obtained with a pH value in the range from 6.0 to 7.0, with the following ratio of components, mass%: succinic acid 5.00-12.5 inosine 1.00-2.40 nicotinamide 0.50-1.20 riboflavin mononucleotide sodium 0.10-0.24 sodium bicarbonate 13.7-17.2 water up to 100.0%.

3. A method for obtaining a stabilized pharmaceutical composition according to paragraph 1, characterized in that sodium bicarbonate is additionally introduced into the composition until a stable solution is obtained with a pH value in the range from 6.4 to 7.4, with the following ratio of components, mass%: succinic acid 5.00-12.50 inosine 1.00-2.40 nicotinamide 0.50-1.20 riboflavin mononucleotide sodium 0.10-0.24 stabilizing agent 3.21-33.06 sodium bicarbonate 0.10-2.90 water up to 100.0%.